ERBB4 G1109C
|
Head and Neck Cancer
|
ERBB4 G1109C
|
Head and Neck Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
ERBB4 G1109C
|
Esophageal Cancer
|
ERBB4 G1109C
|
Esophageal Cancer
|
erlotinib Resistant: D – Preclinical
|
erlotinib Resistant: D – Preclinical
|
ERBB4 G1109C
|
Esophageal Cancer
|
ERBB4 G1109C
|
Esophageal Cancer
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
ERBB4 G1109C
|
Esophageal Cancer
|
ERBB4 G1109C
|
Esophageal Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
ERBB4 G1109C
|
SCCHN
|
ERBB4 G1109C
|
SCCHN
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|